scholarly journals Health-Related Quality of Life among Chronic Opioid Users, Nonchronic Opioid Users, and Nonopioid Users with Chronic Noncancer Pain

2018 ◽  
Vol 53 (5) ◽  
pp. 3329-3349 ◽  
Author(s):  
Corey J. Hayes ◽  
Xiaocong Li ◽  
Chenghui Li ◽  
Anuj Shah ◽  
Niranjan Kathe ◽  
...  
2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Dalila R. Veiga ◽  
Liliane Mendonça ◽  
Rute Sampaio ◽  
José C. Lopes ◽  
Luís F. Azevedo

Background. High rates of opioid use for chronic noncancer pain (CNCP) have been reported worldwide, despite its association with adverse events, inappropriate use, and limited analgesic effect. Opioid-induced constipation (OIC) is the most prevalent and disabling adverse effect associated with opioid therapy. Our aim was to assess the incidence, health related quality of life (HRQOL), and disability in OIC patients. Methods. A prospective cohort study was performed, with 6 months of follow-up, of adult CNCP patients consecutively admitted in 4 multidisciplinary pain clinics (MPC). Demographic and clinical data have been collected. Brief Pain Inventory (BPI) and Short version of Treatment Outcomes in Pain Survey (S-TOPS) were used to measure functional outcomes and HRQOL. OIC was assessed using Bowel Function Index (BFI). Results. 694 patients were recruited. OIC prevalence at baseline was 25.8%. At 6 months, OIC incidence was 24.8%. Female gender (OR = 1.65, p=0.039), opioid therapy (OR 1.65, p=0.026), and interference pain score on BPI (OR 1.10, p=0.009) were identified as OIC independent predictors. OIC patients presented higher disability and pain interference and severity scores. OIC patients reported less satisfaction with outcome (p=0.038). Discussion. Constipation is a common adverse event among opioid users with major functional and quality of life impairment. These findings emphasise the need of OIC adequate assessment and management.


Pain Practice ◽  
2014 ◽  
Vol 15 (4) ◽  
pp. 333-342 ◽  
Author(s):  
Kate L. Lapane ◽  
Brian J. Quilliam ◽  
Carmela Benson ◽  
Wing Chow ◽  
Myoung S. Kim

2019 ◽  
Vol 156 (6) ◽  
pp. S-988
Author(s):  
Swathi Eluri ◽  
Shweta Bhatia ◽  
Shiyan O. Shoyoye ◽  
Ashley Arrington ◽  
Jacquelyn Covington ◽  
...  

2010 ◽  
Vol 15 (4) ◽  
pp. 213-217 ◽  
Author(s):  
C Peter N Watson ◽  
Judy Watt-Watson ◽  
Mary Chipman

BACKGROUND: The use of opioids for chronic noncancer pain (CNCP) remains controversial. Despite a number of randomized controlled trials showing efficacy and safety in the short term, long-term data are limited.OBJECTIVE: To survey a selected cohort of patients with intractable CNCP with regard to long-term efficacy and safety of opioids.METHODS: The present study reports long-term results from a survey of 84 patients with CNCP. The majority of patients had neuropathic pain, were treated with opioids and were followed every three months for a median of 8.4 years. Outcomes examined were pain severity, adverse effects, pain relief, satisfaction, mood, problematic opioid use, tolerance, physical dependency, functional status, health-related quality of life, immune status, sexual function, morbidity and mortality. Measures included a numerical rating scale, the Hospital Anxiety and Depression Scale, Brief Pain Inventory interference scale, Pain Disability Index and Short-Form Health Survey 12, version 2.RESULTS AND CONCLUSIONS: Both long- and short-acting opioids were reported to be effective, with few significant long-term adverse effects in many subjects in the present selected cohort. The majority of patients reported at least 50% or greater pain relief and a moderate improvement in disability. Functional status and health-related quality of life scores were not severely affected. Problematic opioid use, tolerance and serious adverse effects, including constipation, were not major issues. The authors emphasize that the results obtained in the present selected group may not be generalizable to all CNCP patients in whom opioids are being initiated.


2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Bruce D. Dick ◽  
Saifudin Rashiq ◽  
Michelle J. Verrier ◽  
Arto Ohinmaa ◽  
Julie Zhang

Chronic noncancer pain is a prevalent problem associated with poor quality of life. While symptom burden is frequently mentioned in the literature and clinical settings, this research highlights the considerable negative impact of chronic pain on the individual. The 15D, a measure of health-related quality of life (HRQOL), is a user-friendly tool with good psychometric properties. Using a modified edmonton symptom assessment scale (ESAS), we examined whether demographics, medical history, and symptom burden reports from the ESAS would be related statistically to HRQOL measured with the 15D. Symptom burden, medication detriment scores, and number of medical comorbidities were significant negative predictors of 15D scores with ESAS symptom burden being the strongest predictor. Our findings highlight the tremendous symptom burden experienced in our sample. Our data suggest that heavier prescription medication treatment for chronic pain has the potential to negatively impact HRQOL. Much remains unknown regarding how to assess and improve HRQOL in this relatively heterogeneous clinical population.


Sign in / Sign up

Export Citation Format

Share Document